Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. [electronic resource]
Producer: 20170705Description: 575-585 p. digitalISSN:- 1365-2796
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.